Now Recruiting for LightforPd Clinical Trial!
Know someone with Parkinson’s? If your loved one is managing PD, this could be the opportunity they’ve been hoping for. A new, at-home trial for PD is underway. No travel required.
Now Recruiting for LightforPd Clinical Trial!
Know someone with Parkinson’s? If your loved one is managing PD, this could be the opportunity they’ve been hoping for. A new, at-home trial for PD is underway. No travel required.
ADDRESSING MAJOR UNMET NEEDS
A Breakthrough Therapy for People Living with Parkinson’s Disease
Specialized phototherapy addresses both motor and non-motor symptoms
Over 11 million people worldwide live with Parkinson’s disease (PD), a number that is projected to double over the next 20 years. As with so many other neurodegenerative diseases, there have been no major breakthroughs in Parkinson’s disease in decades.
Our personalized at-home device promises to be one of the most significant therapeutic breakthroughs in Parkinson’s disease in decades. We have seen large improvements in our proof-of-concept studies – especially in addressing major unmet needs in Parkinson’s. We are initiating a pivotal trial of our key product, Celeste® specialized phototherapy, to confirm safety and sustained efficacy.
Despite the efficacy of dopaminergic drugs, people with PD continue to experience difficulties with unresolved motor symptoms and non-motor symptoms (e.g., sleep disorders, fatigue, and mood and cognitive problems). Impaired function significantly reduces quality of life for many, often preventing those living with PD from working, exercising, socializing, and doing the things they want to do.
We invite you to join us to improve the lives of individuals suffering from neurodegenerative diseases.
Seeing Specialized Phototherapy Clearly
Our non-invasive specialized phototherapy is well on its way to becoming a physician-prescribed standard of care.
When it comes to motor and non-motor symptoms of Parkinson’s, here’s what we’re seeing so far.
PROMISING RESULTS
and enjoyed improved quality of life.
NON-INVASIVE
LIFESTYLE FRIENDLY PROTOCOL
Warren Olanow, MD (1941-2024)
Distinguished physician, researcher, colleague, father, and friend
The entire PhotoPharmics team mourns the passing of Dr. C. Warren Olanow, a pivotal figure in neurology and chairman of our Clinical and Scientific Advisory Board. Dr. Olanow’s groundbreaking work in Parkinson’s and neurodegenerative research has profoundly advanced our understanding and treatment of movement disorders. His legacy will forever inspire our mission. We extend our heartfelt condolences to his family and honor his lifelong dedication to improving patient lives.
The world is less rich without his presence.
Trending Topics
Parkinson’s Iceberg: The Non-Motor Symptoms You Don’t See
Introduction “My father experienced hallucinations and delusions, and at the time, we didn't realize these symptoms were part of his Parkinson's disease. My mom tried to shield my family and carry the burden alone each day. I wish l'd known there was more to...
An Overview of Parkinson’s Disease
What is Parkinson’s? Parkinson’s Disease (PD) is a complex neurodegenerative disorder that affects the nervous system and progressively worsens over time. While motor symptoms—such as tremors, stiffness, and slow movement—are often the most observable and commonly...
PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting
Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial Salt Lake City, Utah — December 5, 2024 — PhotoPharmics, a pioneer in non-invasive phototherapy for neurological disorders, today announced it will present a poster titled “An...
PhotoPharmics Announces First Subject Completes FDA Pivotal Clinical Trial for the Celeste Device in Parkinson’s
Milestone Marks Significant Progress in Establishing Non-invasive Phototherapy Treatment for Parkinson's Disease Salt Lake City, Utah, September 29, 2024 — PhotoPharmics, a leader in non-invasive phototherapy for neurological disorders, has reached a significant...
PhotoPharmics Welcomes Three Renowned Experts to Its Clinical & Scientific Advisory Board
Company Strengthens Its Leadership in Neurodegenerative Disease Research with New Advisory Board Members PhotoPharmics, an innovator in light-based therapies for neurodegenerative diseases, proudly announces the appointment of three eminent experts to its Clinical...